Get a Second Opinion at SCCA
The Seattle Cancer Care Alliance (SCCA) Prostate Oncology Center takes a multidisciplinary approach to prostate cancer and has set the standard of care for the nation. Through your experienced SCCA team you have access to the full spectrum of leading-edge treatments, including new options available through clinical studies, so we can tailor your care to the characteristics of your disease.
Better Survival Rates for Prostate Cancer
Studies have shown that the chances of surviving prostate cancer depend on where you’re treated, and the first treatment patients receive for cancer is by far the most important. On average, prostate cancer patients who begin their treatment at SCCA have better survival rates than those who started treatment elsewhere.
Experienced, Multidisciplinary Approach
Our doctors specialize in prostate and genitourinary cancers and are nationally known experts in treating these diseases. Our focus on precision medicine—understanding more about the unique characteristics of each patient’s tumor—means our team of doctors, nurses, and other care providers can customize your care. SCCA patients benefit from the breadth and depth of our experience and our multidisciplinary approach, which brings together experts from urologic oncology, radiation oncology, medical oncology, and research.
SCCA offers the latest in prostate cancer treatment—from laparoscopic robot-assisted surgery to proton therapy to the newest treatments developed over the last few years. In addition, tomorrow’s treatments are available to patients who elect to take part in one of the many prostate cancer clinical studies.
Nationally Recognized Expertise
SCCA is the only National Cancer Institute-designated comprehensive cancer center in the Northwest.
The Institute for Prostate Cancer Research (IPCR)—a collaborative effort of UW Medicine and Fred Hutchinson Cancer Research Center, two of SCCA’s founding organizations—brings together a world-renowned team whose mission is to understand the causes and progression of prostate cancer, develop new prevention strategies, devise innovative diagnostics, and improve survival and quality of life. IPCR has already identified or assembled up to 80 percent of the genes expressed in prostate cancer, developed one of the largest serum and tissue banks in the world, undertaken some of the most advanced studies of bone biology and skeletal metastases, assembled information and genotypes for more than 300 families with hereditary prostate cancer, and developed many new therapeutic strategies.
SCCA has researchers on the Stand Up 2 Cancer Prostate Cancer Dream Team, and SCCA received a Specialized Program of Research Excellence (SPORE) grant for our prostate cancer science expertise and a Department of Defense (DOD) Clinical Trials Consortium grant for our clinical studies expertise. The SPORE grant was awarded to only 11 institutions around the country and the DOD grant to only 13. SCCA is one of only five institutions with both of these important research grants currently funded—a testament to our leadership in treating and curing prostate cancer.
Together, our scientists and clinicians provide hope for men with prostate cancer and their families not only in the Northwest but also around the world.